Latest From LG Group
Merger and acquisition deals in South Korea’s pharma/biotech sector have remained relatively few compared to other countries, but several factors are now pointing to a possible increase in activity as pharma and biotech firms hunt for new technologies and growth.
LG's decision to merge its biopharma affiliate LG Life Sciences with the group's main cash cow, LG Chem, signals a focus on "red biotech" and a desire to keep up with other major South Korean conglomerates such as Samsung that are building their biopharma businesses. LG plans to sharply hike sector R&D and capital investments to position the combined operation as a future growth engine.
Pfizer’s Albert Bourla and Hiroshi Matsumori on Established Brands In Japan: An Interview With PharmAsia News
Last week’s exclusive partnership with Mylan has put Pfizer in a much stronger position in Japan’s generics market. The question remains whether it can navigate Japan’s unique Gx challenges.
- Therapeutic Areas
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- LG Group
- Senior Management
- Bon-Moo Koo, Chmn.
- Contact Info
Phone: (82) 2 787 5114
20 Yeouido-dong, Yeongdeungpo-gu
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.